Veradigm | MDRX - Sales Revenues


Veradigm reported $142.52M in Sales Revenues for its fiscal quarter ending in December of 2022.





Sales Change Date
Alcidion AUD 25.47M 2.32M Dec/2025
Ambu A/S DKK 1.57B 10M Mar/2026
Amplifon EUR 579.9M 72.1M Mar/2026
Cardinal Health USD 60.9B 4.73B Mar/2026
Centene USD 49.94B 210M Mar/2026
Charles River Laboratories USD 995.8M 1.6M Mar/2026
Cigna USD 68.52B 3.95B Mar/2026
Coloplast 7.04B 83M Dec/2025
Computer Programs Systems USD 87.79M 3.96M Dec/2025
Convatec Group USD 1.26B 80M Dec/2025
CVS Health USD 100.4B 5.3B Mar/2026
Diasorin EUR 292.51M 2.49M Mar/2026
Elevance Health USD 49.5B 200M Mar/2026
General Electric Aerospace USD 11.6B 270M Mar/2026
Gulf Medical Proj AED 213.77M 25.43M Dec/2025
Humana USD 39.65B 7.13B Mar/2026
IQVIA Holdings USD 4.15B 210M Mar/2026
Laboratory Of America USD 3.54B 20M Mar/2026
Maximus USD 1.31B 40M Mar/2026
McKesson USD 92.3B 13.86B Mar/2026
Med Life RON 787.96M 8.36M Sep/2025
Molina Healthcare USD 10.8B 580M Mar/2026
Omnicell USD 309.88M 4.12M Mar/2026
Oriola-kd EUR 502M 38.7M Dec/2025
Owens Minor USD 708.97M 11.71M Dec/2025
Quest Diagnostics USD 2.9B 90M Mar/2026
Rede D'or Sao Luiz BRL 14.56B 180M Mar/2026
Siemens Healthineers EUR 5.68B 280M Mar/2026
Sonova Holding CHF 1.82B 216.8M Dec/2025
Supermax Corporation Bhd MYR 187.44M 18.13M Dec/2025
UnitedHealth USD 111.7B 1.5B Mar/2026
Veeva Systems USD 835.95M 24.72M Dec/2025
Veradigm USD 142.52M 9.38M Dec/2022
Xerox USD 2.03B 70M Dec/2025